ACCELERATING ONCOLOGY DRUG DEVELOPMENT AND INNOVATIVE STRATEGIES IN CLINICAL TRIALS

Oncodistinct Network logo - ACCELERATING ONCOLOGY DRUG DEVELOPMENT AND INNOVATIVE STRATEGIES IN CLINICAL TRIALS

Dynamic and efficient, the Oncodistinct Network aims to respond to the exponential changes in the oncology research landscape by accelerating treatment individualization, promoting multidisciplinarity and challenging current practices, particularly in settings with unmet medical need. Oncodistinct is a research Network bringing together academic lead investigators sharing the same vision of innovative clinical research. By building a strong collaboration between clinicians, scientists and our partners in drug development, we intent to develop early-to-later phases clinical trials based on cutting-edge designs and high-level translational research components with the aim to improve significantly patient outcomes.

Dynamic

Accelerating treatment individualization, promoting multidisciplinarity and challenging current practices

Innovative

Developing early to later phases based on cutting-edge designs

Collaborative

Building a strong collaboration between clinicians, scientists and stakeholders of clinical research

Network

A network so far composed of 11 comprehensive cancer centers and 16 university hospitals with expertise in oncology. The centers closely work together to contribute to a common project.

 

Clinical Trials

Oncodistinct studies investigate existing and new therapies in all settings and are not dedicated to a specific trial phase or tumor type. We decide to focus on:
  • New drugs development from phase I to later phases trials
  • Innovative trial designs
  • Unmet medical need projects (e.g. rare tumors, oligometastasis, brain metastasis, inflammatory breast cancer,…)
  • Development of immunotherapy and other new agents in the early setting  (e.g. neoadjuvant,…)
  • Biomarkers studies with high potential for clinical practice
  • “Proof of concept” studies

"Oncodistinct is a research network bringing together academic lead investigators sharing the same vision of innovative clinical research"

Think Tank

The Oncodistinct investigator’s think tank is the forum for scientific discussions, ideas and strategies, proposing innovative research to the Network. The think tank is composed by a large panel of experts in cancer care involved in drugs development.

Organization

The driving force of the Oncodistinct Network is firmly its investigator’s think tank which brings innovative clinical research projects. To govern and manage the Network, the Oncodistinct steering committee has the responsibility of strategic decisions and is composed of one representative per Oncodistinct center. The Oncodistinct coordinating team carries on the decisions of the steering committee and the day-to-day management of activities is supported by research operational teams.

The Oncodistinct coordinating team is composed of six individuals selected by the steering committee:

  • A. Awada (Main contact)
  • N. Kotecki (Executive Officer)
  • G. Argiles
  • L. Decoster
  • A. Gonçalves
  • D. Mukherji 

Oncodistinct network

 

MAIN CONTACT:

ahmad.awada@bordet.be
nuria.kotecki@bordet.be


ADDRESS:

Oncodistinct, Dr Ahmad Awada,
Boulevard de Waterloo, 121
1000 Brussels Belgium